Want to see LUNG full AI Analyst Report?
LUNG Stock Chart & Stats
$1.17
-$0.05(-4.10%)
At close: 4:00 PM EDT
$1.17
-$0.05(-4.10%)
Day’s Range― - ―
52-Week Range$1.13 - $2.89
Previous CloseN/A
Volume238.62K
Average Volume (3M)454.13K
Market Cap
$68.00M
Enterprise Value$55.32
Total Cash (Recent Filing)$55.84M
Total Debt (Recent Filing)$56.21M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 04, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding42,237,200
10 Day Avg. Volume218,977
30 Day Avg. Volume454,128
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside199.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$90.77M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid‑70s gross margins are a durable strength for a medical device franchise: they provide pricing power and margin leverage as volumes recover, allow continued R&D and commercialization spend despite current losses, and buffer input cost swings over the next 2–6 months.
Improved Liquidity And Lower Cash BurnA materially reduced cash burn and a larger, extended credit capacity meaningfully extend runway into 2027. Longer debt maturity and contingent capital reduce near‑term refinancing risk and give the company time to execute commercial and clinical plans without immediate dilutive financing.
Commercial Execution Gains In U.S.Filled leadership, incentive alignment and new treating centers signal durable commercial capacity expansion. As sales hires ramp over multiple quarters, the rebuilt U.S. organization supports sustainable procedure adoption and incremental installed base growth beyond short‑term seasonality.
Bears Say
Persistent Unprofitability And Negative Cash FlowOngoing material losses and negative free cash flow are fundamental constraints: they erode equity, force reliance on external financing, limit strategic investment cadence, and raise the risk of future dilution or covenant pressure if revenue recovery lags expectations over the next several quarters.
Elevated Leverage (debt > Equity)Debt exceeding equity increases financial fragility: higher leverage magnifies earnings volatility, restricts balance sheet flexibility for acquisitions or investments, and raises refinancing and covenant risks—particularly consequential given negative cash flow and multi‑quarter commercialization timelines.
China Shipment Suspension Reduced RevenueLoss of China shipments materially depressed near‑term demand and delays contribution from a large market. Even with renewed registration, calendar‑shifted shipments and distributor restocking mean global growth depends on execution stretching into 2027, creating uncertainty in achieving sustained topline recovery.
Pulmonx News
LUNG FAQ
What was Pulmonx Corporation’s price range in the past 12 months?
Pulmonx Corporation lowest stock price was $1.13 and its highest was $2.89 in the past 12 months.
What is Pulmonx Corporation’s market cap?
Pulmonx Corporation’s market cap is $68.00M.
When is Pulmonx Corporation’s upcoming earnings report date?
Pulmonx Corporation’s upcoming earnings report date is Nov 04, 2026 which is in 95 days.
How were Pulmonx Corporation’s earnings last quarter?
Pulmonx Corporation released its earnings results on Jul 29, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.04.
Is Pulmonx Corporation overvalued?
According to Wall Street analysts Pulmonx Corporation’s price is currently Undervalued.
Does Pulmonx Corporation pay dividends?
Pulmonx Corporation does not currently pay dividends.
What is Pulmonx Corporation’s EPS estimate?
Pulmonx Corporation’s EPS estimate is -0.26.
How many shares outstanding does Pulmonx Corporation have?
Pulmonx Corporation has 42,237,200 shares outstanding.
What happened to Pulmonx Corporation’s price movement after its last earnings report?
Pulmonx Corporation reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 28.8%.
Which hedge fund is a major shareholder of Pulmonx Corporation?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (199.15% Upside)
$3.50 (199.15% Upside)
Blogger Sentiment
Bearish
LUNG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.41%
Trailing 12-Months
Company Description
Pulmonx Corporation
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
LUNG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic picture: multiple operational and financial improvements (notably a nearly 40% reduction in adjusted EBITDA loss, 16% YoY reduction in operating expenses, gross margin expansion, China registration renewal, filled U.S. leadership roles, and reiterated full-year guidance) signal meaningful progress on execution and financial leverage. Near-term challenges remain, including an overall revenue decline driven by the China shipment suspension, ongoing quarterly losses and cash burn, typical seasonality (Q3), and the multi-quarter ramp required for new sales hires and clinical enrollment timelines. On balance, the positive operational and balance-sheet developments outweigh the near-term headwinds, but material execution is still required to convert momentum into sustained revenue growth.View all LUNG earnings summariesLUNG Stock 12 Month Forecast
Average Price Target
$3.50
▲(199.15% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
14.06% Insiders
16.95% Mutual Funds
0.42% Other Institutional Investors
64.48% Public Companies and
Individual Investors